OJEMDA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Ojemda, and what generic alternatives are available?

Ojemda is a drug marketed by Day One Biopharms and is included in two NDAs. There are two patents protecting this drug.

This drug has forty-nine patent family members in twenty-seven countries.

The generic ingredient in OJEMDA is tovorafenib. One supplier is listed for this compound. Additional details are available on the tovorafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Ojemda

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 4, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for OJEMDA?
What are the global sales for OJEMDA?
What is Average Wholesale Price for OJEMDA?

Summary for OJEMDA

International Patents:	49
US Patents:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Patent Applications:	79
What excipients (inactive ingredients) are in OJEMDA?	OJEMDA excipients list
DailyMed Link:	OJEMDA at DailyMed

Drug patent expirations by year for OJEMDA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OJEMDA

Generic Entry Dates for OJEMDA^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 218033 Dosage: FOR SUSPENSION;ORAL
Generic Entry Dates for OJEMDA^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: ⤷ Sign Up NDA: 217700 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for OJEMDA

OJEMDA is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of OJEMDA is ⤷ Sign Up.

This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting OJEMDA

Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

Compounds useful as Raf kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
Day One Biopharms	OJEMDA	tovorafenib	FOR SUSPENSION;ORAL	218033-001	Apr 23, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Day One Biopharms	OJEMDA	tovorafenib	TABLET;ORAL	217700-001	Apr 23, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for OJEMDA

When does loss-of-exclusivity occur for OJEMDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 7354
Patent: COMPUESTOS UTILES COMO INHIBIDORES DE LA RAF QUINASA
Estimated Expiration: ⤷ Sign Up

Australia

Patent: 08273002
Patent: Pyrimidine derivatives useful as Raf kinase inhibitors
Estimated Expiration: ⤷ Sign Up

Brazil

Patent: 0813499
Patent: COMPOSTOS ÚTEIS COMO INIBIDORES DA QUINASE RAF
Estimated Expiration: ⤷ Sign Up

Canada

Patent: 93182
Patent: COMPOSES UTILES EN TANT QU'INHIBITEURS DE LA KINASE RAF (COMPOUNDS USEFUL AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up

Chile

Patent: 08001933
Patent: Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
Estimated Expiration: ⤷ Sign Up

China

Patent: 1784545
Patent: Compounds useful as raf kinase inhibitors
Estimated Expiration: ⤷ Sign Up

Patent: 4370828
Patent: COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up

Patent: 6957314
Patent: 用作RAF激酶抑制剂的嘧啶衍生物 (Compounds useful as Raf kinase inhibitors)
Estimated Expiration: ⤷ Sign Up

Denmark

Patent: 31798
Estimated Expiration: ⤷ Sign Up

European Patent Office

Patent: 67489
Patent: COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE LA KINASE RAF (PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up

Patent: 31798
Patent: DÉRIVÉS DE THIAZOLE UTILES DANS LA PRÉPARATION DES INHIBITEURS DE LA KINASE RAF (THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up

Israel

Patent: 2835
Patent: נגזרות פירימידין,הרכבים רוקחיים שלהם, תהליך להכנתם ושימושיהם כמעכבי raf קינאז (Pyrimidine derivatives , pharmaceutical compositions thereof, process for their manufacture and uses thereof as raf kinase inhibitors)
Estimated Expiration: ⤷ Sign Up

Japan

Patent: 49445
Estimated Expiration: ⤷ Sign Up

Patent: 62622
Estimated Expiration: ⤷ Sign Up

Patent: 10532380
Estimated Expiration: ⤷ Sign Up

Patent: 13256534
Patent: COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up

Patent: 15117249
Patent: ＲＡＦキナーゼ阻害剤として有用な化合物 (COMPOUND USEFUL AS RAF KINASE INHIBITOR)
Estimated Expiration: ⤷ Sign Up

New Zealand

Patent: 2352
Patent: PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up

Russian Federation

Patent: 92166
Patent: СОЕДИНЕНИЯ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ RAF (COMPOUNDS SUITABLE FOR USE AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up

Patent: 09149214
Patent: СОЕДИНЕНИЯ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ RAF
Estimated Expiration: ⤷ Sign Up

South Africa

Patent: 0909223
Patent: PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up

South Korea

Patent: 1650140
Estimated Expiration: ⤷ Sign Up

Patent: 1764076
Estimated Expiration: ⤷ Sign Up

Patent: 100033384
Patent: PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up

Patent: 160027992
Patent: ＲＡＦ 카나아제 억제제로서 유용한 화합물 (PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up

Spain

Patent: 35729
Estimated Expiration: ⤷ Sign Up

Patent: 76169
Estimated Expiration: ⤷ Sign Up

Taiwan

Patent: 44379
Estimated Expiration: ⤷ Sign Up

Patent: 0916467
Patent: Compounds useful as Raf kinase inhibitors
Estimated Expiration: ⤷ Sign Up

Ukraine

Patent: 1478
Patent: СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ КАК ИНГИБИТОРЫ RAF-КИНАЗЫ;СПОЛУКИ, КОРИСНІ ЯК ІНГІБІТОРИ Raf-КІНАЗИ (COMPOUNDS USEFUL AS INHIBITORS OF RAF PROTEIN KINASE)
Estimated Expiration: ⤷ Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OJEMDA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
China	106456787	PAN‑RAF激酶抑制剂的医药调配物、其制备方法以及使用方法 (Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use)	⤷ Sign Up
Australia	2008273002	Pyrimidine derivatives useful as Raf kinase inhibitors	⤷ Sign Up
South Africa	200909223	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	⤷ Sign Up
Eurasian Patent Organization	201691918	ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ ИНГИБИТОРА КИНАЗ СЕМЕЙСТВА RAF, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ	⤷ Sign Up
Costa Rica	20160483	FORMULACIONES FARMACÉUTICAS, PROCESOS PARA LA PREPARACIÓN Y MÉTODOS DE USO	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration